Bayer Shuffles Atara’s CAR-Ts Out Of Its Cell Therapy Deck

Biotech’s Fortunes Riding On Other Assets

 
• By Andrew McConaghie
Bayer, Wuppertal
Bayer will now focus on its in-house cell and gene therapy pipeline via subsidiaries AskBio and BlueRock Therapeutics. • Source: Shutterstock

More from Business

More from Scrip